Nasdaq · CIK 0001756262
TMDX TransMedics Group, Inc.
C
60 / 100
Material weaknesses
2
Restatements
0
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
0
Deductions
40
Remediation credit
0
Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.
Disclosures, in the company's words
“that we have identified a material weakness in our internal control over financial reporting, and that we may identify additional material weaknesses in the future”
“Specifically, the Company has not designed and maintained effective controls over inventory movement within its manufacturing network. While effective controls are in place to verify the existence and accuracy of inventory as of year-end, effective controls have not been designed and maintained to verify that inventory movements are appropriately recorded in the interim financial statements.”
“our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting.”
“that we have identified a material weakness in our internal control over financial reporting, and that we may identify additional material weaknesses in the future”
Filings read
- 8-K · 2026-11-05read
- 10-Q · 2026-11-05read
- 8-K · 2026-09-10queued
- 10-Q · 2026-08-04queued
- 8-K · 2026-08-04queued
- 10-Q · 2026-05-05queued
- 8-K · 2026-05-05queued
- 8-K · 2026-02-27queued
- 8-K · 2026-02-24queued
- 10-K · 2026-02-24queued
- 8-K · 2025-10-29queued
- 10-Q · 2025-10-29queued
- 8-K · 2025-07-30queued
- 10-Q · 2025-07-30queued
- 8-K · 2025-05-08queued
- 10-Q · 2025-05-08queued
- 10-K · 2025-02-27queued
- 8-K · 2025-02-27queued
Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.